{"title":"卫材将CTCL治疗药物Targretin®的美国权利转让给Valeant","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I2.1905","DOIUrl":null,"url":null,"abstract":"Valeant Pharmaceuticals International has acquired US rights to the capsule and gel formulations of Targretin® (bexarotene), which is used to treat skin problems arising from cutaneous T-cell lymphoma, from Eisai for US$65 M upfront plus contingent payments based on certain undisclosed milestones. Eisai, which acquired Targretin from Ligand Pharmaceuticals in 2006, will retain rights outside of the US and will continue to supply product to its sales subsidiaries and distribution partners.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I2.1905\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Valeant Pharmaceuticals International has acquired US rights to the capsule and gel formulations of Targretin® (bexarotene), which is used to treat skin problems arising from cutaneous T-cell lymphoma, from Eisai for US$65 M upfront plus contingent payments based on certain undisclosed milestones. Eisai, which acquired Targretin from Ligand Pharmaceuticals in 2006, will retain rights outside of the US and will continue to supply product to its sales subsidiaries and distribution partners.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I2.1905\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I2.1905","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant
Valeant Pharmaceuticals International has acquired US rights to the capsule and gel formulations of Targretin® (bexarotene), which is used to treat skin problems arising from cutaneous T-cell lymphoma, from Eisai for US$65 M upfront plus contingent payments based on certain undisclosed milestones. Eisai, which acquired Targretin from Ligand Pharmaceuticals in 2006, will retain rights outside of the US and will continue to supply product to its sales subsidiaries and distribution partners.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
